Portal de recerca
Uso de baricitinib en práctica clínica para el tratamiento de la Alopecia Areata grave en España: un estudio observacional.
Dades bàsiques
- Protocol:
- 2022-12110
- EURDRACT:
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2024
- Any de finalització:
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
A Case of Localised Immediate Hypersensitivity Reaction to Bimekizumab.
Lasheras-Perez, Miguel Antonio; (...); Ibanez-Echevarria, Ethel
Article. 10.1111/cod.14774. 2025
Delusional parasitosis (Ekbom's syndrome).
Mansilla-Polo, M, Martin-Torregrosa, D, Botella-Estrada, R
Article. 10.1016/j.semerg.2024.102423. 2024
Dermatologic Consultations for Patients Hospitalized in Non-Dermatologic Wards: Results of a 384-Patient Cross-Sectional Study From a Tertiary Referral Hospital
Mansilla-Polo, M.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2024.10.030. 2024
Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review.
Mansilla-Polo M; (...); Botella-Estrada R
Letter. 10.1111/ddg.15502. 2024
Dermatological toxicities of talquetamab, a new bispecificantibody: case series and literature review
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Letter. 10.1111/ddg.15502_g. 2024
Guselkumab, Risankizumab, and Tildrakizumab demonstrate parallel effectiveness and safety in psoriasis treatment: a head-to-head comparative study in real clinical practice.
Mansilla-Polo M; (...); Botella-Estrada R
Article. 10.1016/j.abd.2024.04.004. 2024
Histological deep margins in cutaneous squamous cell carcinoma of the scalp and risk of recurrence.
Verdaguer-Faja, Julia; (...); Jaka, Ane
Article. 10.1111/jdv.20250. 2024
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma
Gutzmer, Ralf; (...); Hauschild, Axel
Article. 10.1186/s12885-024-13101-z. 2024
Nodular hidradenoma: Case report and brief literature review.
Mansilla-Polo, Miguel; (...); Botella-Estrada, Rafael
Article. 10.1016/j.patol.2025.100801. 2025
Oral Ruxolitinib could Increase the Aggressiveness of Cutaneous Squamous Cell Carcinomas: A 6-Patient Series
Lasheras-Perez, M. A.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2023.07.035. 2025
Recalcitrant Hailey-Hailey Disease With Satisfactory Response to Apremilast
Mansilla-Polo, M.; (...); Botella-Estrada, R.
Letter. 10.1016/j.ad.2024.10.025. 2024
Ruxolitinib oral puede aumentar la agresividad de los carcinomas escamosos cutáneos: serie de 6 pacientes.
Lasheras-Perez MA; (...); Botella-Estrada R
Article. 10.1016/j.ad.2024.10.003. 2025
Sarcoidosis cutánea tras inyecciones de plasma rico en plaquetas y maquillaje permanente de cejas.
Martín-Torregrosa D; (...); Botella-Estrada R
Article. 10.1016/j.ad.2024.10.043. 2024
Study of Microsatellite Instability by Immunohistochemistry in a Cohort of Patients With Melanoma
Diaz, Rodolfo David Palacios; (...); Estrada, Rafael Botella
Article. 10.1111/cup.14758. 2025
Successful Treatment of Mogamulizumab-Associated Rash With Upadacitinib: Evidence From 2 Cases.
Martin-Torregrosa, Daniel; (...); Botella-Estrada, Rafael
Article. 10.1001/jamadermatol.2024.4582. 2024
Sustained response to anti-TNF therapy in ASIA syndrome triggered by vaccination and filler.
Martin-Torregrosa, Daniel; (...); Rodriguez-Serna, Mercedes
Letter. 10.1111/ijd.17650. 2025
Treatment of palmoplantar psoriasis with oral roflumilast: a case series.
Lasheras-Perez, Miguel Antonio; (...); Botella-Estrada, Rafael
Article. 10.1093/ced/llae229. 2024
Use of an electrospun bioveil is safe and does not decrease skin graft take on burn wounds: A randomised, controlled clinical trial.
Perez-Del-Caz, Maria Dolores; (...); Perez-Plaza, Aranzazu
Article. 10.1016/j.burns.2025.107427. 2025